RD Moore, CP Chaulk, R Griffiths, S Cavalcante and RE Chaisson
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Decision analysis was used to compare three alternative strategies for a 6-mo course of treatment for tuberculosis: directly observed drug therapy (DOT), self-administered fixed-dose combination drug therapy, and self-administered conventional individual drug therapy. Estimates of effectiveness were obtained from the published literature. Estimates of costs were obtained from the literature and the Baltimore City Health Department. Both DOT and fixed-dose combination therapy were less costly and more effective than conventional therapy, although DOT was most cost-effective. In total, the average cost per patient treated was $13,925 for DOT, $13,959 for fixed-dose combination therapy, and $15,003 for conventional therapy. Per 1,000 patients treated, 31 relapses and three deaths could be expected for DOT, 96 relapses and eight deaths for fixed-dose combination therapy, and 133 relapses and 13 deaths for conventional therapy. The marginal cost-effectiveness of DOT relative to fixed-dose combination therapy was most sensitive to variability in the direct cost of DOT and less sensitive to relapse rates for DOT and fixed-dose combination therapy. The inferior cost- effectiveness of conventional therapy was not sensitive to plausible variability in cost or effectiveness. Both DOT and fixed-dose combination therapy were cost-effective relative to conventional therapy, although DOT is probably most cost-effective.

This article has been cited by other articles:

				V. J. Flaherman, T. C. Porco, E. Marseille, and S. E. Royce Cost-effectiveness of Alternative Strategies for Tuberculosis Screening Before Kindergarten Entry Pediatrics, July 1, 2007; 120(1): 90 - 99. [Abstract] [Full Text] [PDF]

				R. S. Braithwaite, M. S. Roberts, and A. C. Justice Incorporating Quality of Evidence into Decision Analytic Modeling Ann Intern Med, January 16, 2007; 146(2): 133 - 141. [Abstract] [Full Text] [PDF]

				R. A Elliott, N. Barber, and R. Horne Cost-Effectiveness of Adherence-Enhancing Interventions: A Quality Assessment of the Evidence Ann. Pharmacother., March 1, 2005; 39(3): 508 - 515. [Abstract] [Full Text] [PDF]

				American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662. [Full Text] [PDF]

				E. D Chan and M. D Iseman Current medical treatment for tuberculosis BMJ, November 30, 2002; 325(7375): 1282 - 1286. [Full Text] [PDF]

				L. B. Gerald, S. Tang, F. Bruce, D. Redden, M. E. Kimerling, N. Brook, N. Dunlap, and W. C. Bailey A Decision Tree for Tuberculosis Contact Investigation Am. J. Respir. Crit. Care Med., October 15, 2002; 166(8): 1122 - 1127. [Abstract] [Full Text] [PDF]

				Policy Statements Adopted by the Governing Council of the American Public Health Association, October 24, 2001 Am J Public Health, March 1, 2002; 92(3): 451 - 483. [Full Text] [PDF]

				G H Bothamley, J P Rowan, C J Griffiths, M Beeks, M McDonald, E Beasley, C van den Bosch, and G Feder Screening for tuberculosis: the port of arrival scheme compared with screening in general practice and the homeless Thorax, January 1, 2002; 57(1): 45 - 49. [Abstract] [Full Text] [PDF]

				R. L. Berger, B. R. Celli, A. L. Meneghetti, P. H. Bagley, C. D. Wright, E. P. Ingenito, A. Gray, and G. L. Snider Limitations of randomized clinical trials for evaluating emerging operations: the case of lung volume reduction surgery Ann. Thorac. Surg., August 1, 2001; 72(2): 649 - 657. [Abstract] [Full Text] [PDF]

				R. Dietze, L. Teixeira, L. M. C. Rocha, M. Palaci, J. L. Johnson, C. Wells, L. Rose, K. Eisenach, and J. J. Ellner Safety and Bactericidal Activity of Rifalazil in Patients with Pulmonary Tuberculosis Antimicrob. Agents Chemother., July 1, 2001; 45(7): 1972 - 1976. [Abstract] [Full Text] [PDF]

				T. F. JONES and W. SCHAFFNER Miniature Chest Radiograph Screening for Tuberculosis in Jails . A Cost-effectiveness Analysis Am. J. Respir. Crit. Care Med., July 1, 2001; 164(1): 77 - 81. [Abstract] [Full Text] [PDF]

				K. SCHWARTZMAN and D. MENZIES Tuberculosis Screening of Immigrants to Low-Prevalence Countries . A Cost-effectiveness Analysis Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): 780 - 789. [Abstract] [Full Text] [PDF]

				J. M. FitzGerald, L. Wang, and R. K. Elwood Tuberculosis: 13. Control of the disease among aboriginal people in Canada Can. Med. Assoc. J., February 1, 2000; 162(3): 351 - 355. [Abstract] [Full Text] [PDF]

				D. C. SNYDER and D. P. CHIN Cost-effectiveness Analysis of Directly Observed Therapy for Patients with Tuberculosis at Low Risk for Treatment Default Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 582 - 586. [Abstract] [Full Text]

				D. V. Havlir and P. F. Barnes Tuberculosis in Patients with Human Immunodeficiency Virus Infection N. Engl. J. Med., February 4, 1999; 340(5): 367 - 373. [Full Text] [PDF]

				N. Roche Recent advances: Pulmonary medicine BMJ, January 16, 1999; 318(7177): 171 - 176. [Full Text]

				Joint Tuberculosis Committee of the British Thorac Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998 Thorax, July 1, 1998; 53(7): 536 - 548. [Abstract] [Full Text]

				C. P. Chaulk, V. A. Kazandjian, and for the Public Health Tuberculosis Guidelines Pane Directly Observed Therapy for Treatment Completion of Pulmonary Tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel JAMA, March 25, 1998; 279(12): 943 - 948. [Abstract] [Full Text] [PDF]